Dr. Martens Gestion
Gestion contrôle des critères 3/4
Le PDG Dr. Martens est Ije Nwokorie, nommé en Jan2025, a un mandat de 1.33 ans. La rémunération annuelle totale est £ 303.00K, composée du salaire de 49.8% et des bonus 50.2%, y compris les actions et options de la société. détient directement 0.14% des actions de la société, d'une valeur de £ 935.95K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.5 ans et 4.2 ans.
Informations clés
Ije Nwokorie
Directeur général
UK£303.0k
Rémunération totale
| Pourcentage du salaire du PDG | 49.83% |
| Durée du mandat du directeur général | 1.3yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 4.5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 4.2yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • May 13
DOCS: Future Returns Will Depend On Steady Margins And Long Term Assumptions
Analysts have adjusted their price views on Dr. Martens, reflecting updated assumptions around discount rates, modestly different revenue growth and profit margin expectations, and a slightly altered future P/E multiple. Together, these factors feed into a refreshed £1.41 fair value estimate.Mise à jour du récit • Apr 28
DOCS: Future Returns Will Rely On Profit Focus And Stable Long Term Assumptions
Analysts have adjusted their price targets on Dr. Martens upward to £1.41, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E that are broadly in line with previous estimates but fine tuned to current views. Valuation Changes Fair Value: Modelled fair value remains at £1.41, with no change from the previous estimate.Mise à jour du récit • Apr 11
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their price target on Dr. Martens to £1.41 from £1.41. They point to slightly higher assumed discount rates and modestly different revenue growth and profit margin expectations that keep the overall valuation level broadly unchanged.Mise à jour du récit • Mar 27
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their fair value assumptions slightly, nudging the implied P/E closer to £19.95 and reflecting small updates to discount rate, revenue growth and profit margin expectations for Dr. Martens. What's in the News Issued earnings guidance for fiscal 2026 with revenue expected to be broadly flat on a constant currency basis as the company focuses on the quality of revenue and profitability (company guidance).Mise à jour du récit • Mar 13
DOCS: Future Returns Will Depend On Profit-Led Flat Revenue Guidance In 2026
Analysts have nudged their price target for Dr. Martens higher to £1.41, citing modest adjustments to assumptions about the discount rate, revenue, profit margin and future P/E in their updated models. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).Mise à jour du récit • Feb 27
DOCS: Future Returns Will Depend On Prioritising Profitability Over Near Term Revenue Expansion
Analysts have lifted their price target for Dr. Martens to £1.41, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin and future P/E that collectively point to a modestly improved risk and earnings profile. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).Article d’analyse • Feb 12
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0085
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0085 per share on the 9th of April. This...Mise à jour du récit • Feb 10
DOCS: Future Returns Will Depend On Expanding Reclaimed Leather Sustainability Collaboration
Analysts have adjusted their price targets for Dr. Martens modestly, reflecting revised assumptions around the discount rate, expected revenue growth, profit margins and a higher future P/E multiple, which together temper the valuation outlook while still supporting a measured premium on earnings. What's in the News Dr. Martens and materials company Gen Phoenix are marking four consecutive seasons of collaboration, extending their work with reclaimed leather under the Genix Nappa line.Mise à jour du récit • Jan 26
DOCS: Future Returns Will Rely On Reclaimed Leather Sustainability Partnership
Analysts have adjusted their price targets for Dr. Martens, reflecting updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple. Taken together, these factors point to a revised view of the shares' potential value, even though the fair value estimate remains at £1.41.
Mise à jour du récit • Jan 11
DOCS: Future Returns Will Rely On Margins And Long Term Sustainability Partnership
Analysts have made a modest trim to their price target on Dr. Martens, reflecting slightly adjusted assumptions around discount rates, revenue growth, profit margins and future P/E, while still seeing the shares as aligned with an updated fair value of 0.8x. What's in the News Dr. Martens and Gen Phoenix mark four consecutive seasons of working together on reclaimed leather products under the Genix Nappa line, highlighting a multi year partnership rather than a short pilot or capsule approach (Key Developments).Mise à jour du récit • Dec 26
DOCS: Future Returns Will Depend On Margin Execution And Sustainability Delivery
Analysts have modestly adjusted their price target on Dr. Martens to 75 GBp, reflecting slightly higher long term revenue growth and profit margin assumptions while maintaining a broadly Neutral stance. Analyst Commentary Analyst commentary around Dr. Martens has remained measured, with the latest work reiterating a Neutral stance and a 75 GBp price target, signaling limited upside in the near term.Mise à jour du récit • Dec 12
DOCS: Modest Upside Outlook Will Hinge On Margin Recovery And Sustainability Expansion
The analyst price target for Dr. Martens has been modestly raised to £0.80 from £0.75, as analysts factor in slightly stronger expectations for revenue growth, profit margins, and future earnings multiples, while still maintaining a cautious overall stance. Analyst Commentary Recent Street research has reinforced a measured stance on Dr. Martens, with coverage reinstated at a neutral rating and a price target that sits below longer term historical trading levels.Article d’analyse • Dec 01
Shareholders Should Be Pleased With Dr. Martens plc's (LON:DOCS) Price
Dr. Martens plc's ( LON:DOCS ) price-to-earnings (or "P/E") ratio of 48.9x might make it look like a strong sell right...Article d’analyse • Nov 04
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 26% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.13 based on 2 Stage Free Cash Flow to Equity Dr. Martens...
Mise à jour du récit • Oct 08
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Analysts have raised their price target on Dr. Martens from £0.80 to £1.12 per share, citing expectations that 2025 will mark a turning point for the company and stating that market valuations do not yet reflect its long-term growth potential. Analyst Commentary Market watchers have offered mixed insights following the recent upgrade and price target increase for Dr. Martens.Article d’analyse • Aug 26
Returns On Capital Signal Tricky Times Ahead For Dr. Martens (LON:DOCS)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Mise à jour du récit • Aug 19
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Despite a notable downgrade in forecast revenue growth and a higher projected future P/E, analysts have nonetheless raised Dr. Martens’ consensus price target from £0.898 to £0.952. What's in the News The Board of Dr. Martens proposed a final dividend of 1.70 pence, maintaining the total dividend for fiscal year 2025 at 2.55 pence, equal to the prior year, pending shareholder approval.Article d’analyse • Aug 05
Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Dr. Martens fair value estimate is UK£1.09 Dr. Martens...Article d’analyse • Jun 18
Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017
Dr. Martens plc's ( LON:DOCS ) dividend will be increasing from last year's payment of the same period to £0.017 on 8th...Article d’analyse • Jun 15
Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings
Dr. Martens plc's ( LON:DOCS ) stock was strong despite it releasing a soft earnings report last week. Our analysis...Article d’analyse • Apr 15
Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Nouveau récit • Mar 14
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Strategic focus on premium positioning, demand planning, and cost reductions aims to enhance revenue, margins, and profitability.Article d’analyse • Dec 06
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%
Dr. Martens plc ( LON:DOCS ) shareholders would be excited to see that the share price has had a great month, posting a...Article d’analyse • Dec 01
Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year
The investors in Dr. Martens plc 's ( LON:DOCS ) will be rubbing their hands together with glee today, after the share...Article d’analyse • Sep 21
Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet
The Dr. Martens plc ( LON:DOCS ) share price has fared very poorly over the last month, falling by a substantial 30...Article d’analyse • Aug 20
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?
Key Insights Dr. Martens' estimated fair value is UK£1.31 based on 2 Stage Free Cash Flow to Equity Dr. Martens...Article d’analyse • Jul 20
Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Article d’analyse • Jun 19
There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings
The market was pleased with the recent earnings report from Dr. Martens plc ( LON:DOCS ), despite the profit numbers...Article d’analyse • May 21
Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Dr. Martens plc ( LON:DOCS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Article d’analyse • Mar 27
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Article d’analyse • Mar 06
Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Article d’analyse • Feb 08
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.32 based on 2 Stage Free Cash Flow to Equity Dr. Martens...Article d’analyse • Jan 21
Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
With a price-to-earnings (or "P/E") ratio of 6.9x Dr. Martens plc ( LON:DOCS ) may be sending very bullish signals at...Article d’analyse • Jan 03
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0156 per share on the 2nd of February...Article d’analyse • Dec 13
Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dr. Martens plc's ( LON:DOCS ) investors are due to receive a payment of £0.0156 per share on 2nd of February. This...Article d’analyse • Oct 12
Dr. Martens (LON:DOCS) Is Very Good At Capital Allocation
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Article d’analyse • Sep 13
Calculating The Intrinsic Value Of Dr. Martens plc (LON:DOCS)
Key Insights Dr. Martens' estimated fair value is UK£1.88 based on 2 Stage Free Cash Flow to Equity Current share price...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 29 2026 | n/a | n/a | UK£24m |
| Dec 29 2025 | n/a | n/a | UK£20m |
| Sep 28 2025 | n/a | n/a | UK£15m |
| Jun 28 2025 | n/a | n/a | UK£10m |
| Mar 30 2025 | n/a | n/a | UK£5m |
| Dec 30 2024 | n/a | n/a | UK£17m |
| Sep 29 2024 | n/a | n/a | UK£29m |
| Jun 29 2024 | n/a | n/a | UK£49m |
| Mar 31 2024 | UK£57k | n/a | UK£69m |
| Dec 31 2023 | n/a | n/a | UK£86m |
| Sep 30 2023 | n/a | n/a | UK£103m |
| Jun 30 2023 | n/a | n/a | UK£116m |
| Mar 31 2023 | UK£67k | n/a | UK£129m |
| Dec 31 2022 | n/a | n/a | UK£153m |
| Sep 30 2022 | n/a | n/a | UK£177m |
| Jun 30 2022 | n/a | n/a | UK£179m |
| Mar 31 2022 | UK£65k | n/a | UK£181m |
| Dec 31 2021 | n/a | n/a | UK£118m |
| Sep 30 2021 | n/a | n/a | UK£54m |
| Jun 30 2021 | n/a | n/a | UK£44m |
| Mar 31 2021 | UK£11k | n/a | UK£35m |
Rémunération vs marché: La rémunération totale de Ije ($USD 407.12K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 1.58M ).
Rémunération et revenus: La rémunération de Ije a augmenté de plus de 20 % au cours de l'année écoulée.
PDG
Ije Nwokorie (55 yo)
1.3yrs
Titularisation
UK£303,000
Compensation
Mr. Onyeije Ogueri Nwokorie, also known as Ije, is CEO & Director at Dr. Martens Limited since January 06, 2025. He was Chief Brand Officer at Dr. Martens plc since February 01, 2024. He is Independent Non...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Executive Director | 1.3yrs | UK£303.00k | 0.14% £ 936.0k | |
| CFO & Director | 2yrs | UK£1.78m | 0.027% £ 177.3k | |
| Chief Operating Officer | 7.9yrs | pas de données | pas de données | |
| Chief Technology Officer | no data | pas de données | pas de données | |
| Director of Investor Relations & Corporate Communications | no data | pas de données | pas de données | |
| Chief People Officer | no data | pas de données | pas de données | |
| Chief Digital Officer | 8.1yrs | pas de données | pas de données | |
| President of APAC | 6.7yrs | pas de données | pas de données | |
| Chief Product Officer | 4.4yrs | pas de données | pas de données | |
| President of Americas | 4.5yrs | pas de données | pas de données | |
| President of EMEA | 3yrs | pas de données | pas de données | |
| Director of Sustainability | no data | pas de données | pas de données |
4.5yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: L'équipe de direction de DOCS est considérée comme expérimentée (ancienneté moyenne 4.5 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Executive Director | 1.3yrs | UK£303.00k | 0.14% £ 936.0k | |
| CFO & Director | 2yrs | UK£1.78m | 0.027% £ 177.3k | |
| Independent Non-Executive Director | 1.2yrs | UK£1.00k | 0.021% £ 135.6k | |
| Independent Non-Executive Director | 3yrs | UK£68.00k | 0.0079% £ 51.9k | |
| Non-Independent Non-Executive Director | 1.2yrs | pas de données | pas de données | |
| Independent Non-Executive Director | 5.3yrs | UK£68.00k | 0.0021% £ 13.7k | |
| Independent Non-Executive Director | 5.3yrs | UK£96.00k | 0.010% £ 67.3k | |
| Representative Non-Independent Non-Executive Director | 5.3yrs | pas de données | pas de données | |
| Senior Independent Non-Executive Director | 5.3yrs | UK£101.00k | 0.0048% £ 31.2k | |
| Chair of the Board | 10.7yrs | UK£342.00k | 0.81% £ 5.3m |
4.2yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de DOCS sont considérés comme expérimentés (ancienneté moyenne 4.2 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 15:56 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/29 |
| Revenus annuels | 2026/03/29 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Dr. Martens plc est couverte par 13 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Richard Taylor | Barclays |
| Anne Critchlow | Berenberg |
| David Roux | BofA Global Research |